143 related articles for article (PubMed ID: 21861801)
21. Renal cell carcinoma: how to hit the targets?
Banyra O; Tarchynets M; Shulyak A
Cent European J Urol; 2014; 66(4):394-404. PubMed ID: 24757527
[TBL] [Abstract][Full Text] [Related]
22. Renal cell carcinoma with non-clear cell histologies: all the same peas in one pod?
Roussel E; Amparore D; Bertolo R; Erdem S; Marchioni M; Pavan N; Campi R;
Minerva Urol Nephrol; 2023 Aug; 75(4):529-531. PubMed ID: 37530663
[No Abstract] [Full Text] [Related]
23. The value of IMmotion010 for rare kidney cancer histologies.
Iannantuono GM; Chandran E; Apolo AB
Lancet; 2023 Jul; 402(10397):181. PubMed ID: 37453746
[No Abstract] [Full Text] [Related]
24. Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trial.
Halabi S; Yang Q; Carmack A; Zhang S; Foo WC; Eisen T; Stadler WM; Jones RJ; Garcia JA; Vaishampayan UN; Picus J; Hawkins RE; Hainsworth JD; Kollmannsberger CK; Logan TF; Puzanov I; Pickering LM; Ryan CW; Protheroe A; George DJ; Armstrong AJ
Kidney Cancer J; 2021 Oct; 19(3):64-72. PubMed ID: 34765076
[TBL] [Abstract][Full Text] [Related]
25. Sunitinib in the treatment of metastatic renal cell carcinoma.
Schmid TA; Gore ME
Ther Adv Urol; 2016 Dec; 8(6):348-371. PubMed ID: 27904651
[TBL] [Abstract][Full Text] [Related]
26. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.
Armstrong AJ; Halabi S; Eisen T; Broderick S; Stadler WM; Jones RJ; Garcia JA; Vaishampayan UN; Picus J; Hawkins RE; Hainsworth JD; Kollmannsberger CK; Logan TF; Puzanov I; Pickering LM; Ryan CW; Protheroe A; Lusk CM; Oberg S; George DJ
Lancet Oncol; 2016 Mar; 17(3):378-388. PubMed ID: 26794930
[TBL] [Abstract][Full Text] [Related]
27. Toxicities of targeted agents in advanced renal cell carcinoma.
Patel P; Srinivas S
Curr Clin Pharmacol; 2011 Aug; 6(3):181-8. PubMed ID: 21827392
[TBL] [Abstract][Full Text] [Related]
28. Non-clear cell advanced kidney cancer: is there a gold standard?
Sánchez P; Calvo E; Durán I
Anticancer Drugs; 2011 Jan; 22 Suppl 1():S9-14. PubMed ID: 21173605
[TBL] [Abstract][Full Text] [Related]
29. Differentiating mTOR inhibitors in renal cell carcinoma.
Pal SK; Quinn DI
Cancer Treat Rev; 2013 Nov; 39(7):709-19. PubMed ID: 23433636
[TBL] [Abstract][Full Text] [Related]
30. Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies.
Kroeger N; Pantuck AJ; Wells JC; Lawrence N; Broom R; Kim JJ; Srinivas S; Yim J; Bjarnason GA; Templeton A; Knox J; Bernstein E; Smoragiewicz M; Lee J; Rini BI; Vaishampayan UN; Wood LA; Beuselinck B; Donskov F; Choueiri TK; Heng DY
Eur Urol; 2015 Sep; 68(3):506-15. PubMed ID: 25524810
[TBL] [Abstract][Full Text] [Related]
31. Therapy for non-clear cell histologies in renal cancer.
Bitting RL; Madden J; Armstrong AJ
Curr Clin Pharmacol; 2011 Aug; 6(3):169-80. PubMed ID: 21861801
[TBL] [Abstract][Full Text] [Related]
32. Molecular Targets and Angiogenesis in Renal Cell Carcinoma, A Multitarget Approach: Mini Review.
Badal SAM; Aiken WD; Chin SN
Curr Drug Targets; 2017; 18(10):1204-1213. PubMed ID: 27138755
[TBL] [Abstract][Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]